Recent insider selling of Avanos Medical stock, particularly by Senior VP Michael Greiner, is concerning. Insiders' lack of significant ownership and their share selling could deter potential investors.

Unresolved challenges may be indicated by weak growth and share price performance. The market's focus is likely on revenue due to the company's lack of profits. Accelerated revenue growth or profits could attract more interest in the stock.

Analysts predict a below-average future growth rate for Avanos Medical despite its high P/E ratio. This warns of a possible risk for investors, who might pay a premium not supported by the earnings outlook.